Celiprolol Hydrochloride

57470-78-7 Categories: , ,
  • #LGM Pharma is a Celiprolol Hydrochloride CAS# 57470-78-7 API supplier distributor based in the USA. Inquire about DMF, cGMP, price, availability, delivery, purity, and more.
  • #Questions? Call our customer API support number 1-(800)-881-8210.
  • #LGM Pharma offers this active ingredient but not the finished dosage forms.

Product Details:

  • CAS No: 57470-78-7
  • AHFC code:
  • Synonyms: 3-(3-Acetil-4-(3-tert-butilamino-2-hidroxipropoxi)fenil)-1,1-dietilurea HCl, 3-(3-Acetil-4-(3-tert-butilamino-2-hidroxipropoxi)fenil)-1,1-dietilurea HCl [Spanish], 3-(3-Acetyl-4-(3-(tert-butylamino)-2-hydroxypropoxy)phenyl)-1,1-diethylurea monohydrochloride, 3-(3-Acetyl-4-(3-tert-butylamino-2-hydroxypropoxy)phenyl)-1,1-diethylharnstoff HCl, 3-(3-Acetyl-4-(3-tert-butylamino-2-hydroxypropoxy)phenyl)-1,1-diethylharnstoff HCl [German], 3-(3-Acetyl-4-(3-tert-butylamino-2-hydroxypropoxy)phenyl)-1,1-diethylurea hydrochloride, CCRIS 1095, Celiprolol clorhidrato, Celiprolol clorhidrato [Spanish], Celiprolol HCl, Celiprolol hydrochlorid, Celiprolol hydrochlorid [German], Celiprolol hydrochloride, Clorhidrato de celiprolol, Clorhidrato de celiprolol [Spanish], EINECS 260-752-2, Selecor, Selectrol, St 1396, UNII-G1M3398594, Urea, N'-(3-acetyl-4-(3-((1,1-dimethylethyl)amino)-2-hydroxypropoxy)phenyl)-N,N-diethyl-, monohydrochloride
  • ATC Code:
  • Chemical Formula: C20-H33-N3-O4.Cl-H
  • Molecular Weight: 415.959
  • Assay/Purity: Typically NLT 98%
  • DrugBank: DB04846
  • SMILES: c1(c(cc(NC(N(CC)CC)=O)cc1)C(C)=O)OC[C,,H](CNC(C)(C)C)O.Cl
  • InChl: 1S/C20H33N3O4.ClH/c1-7-23(8-2)19(26)22-15-9-10-18(17(11-15)14(3)24)27-13-16(25)12-21-20(4,5)6;/h9-11,16,21,25H,7-8,12-13H2,1-6H3,(H,22,26);1H
  • PubChem:
  • IUPAC:

Additional Details

Mode of Action:
General Reference:
Ong KT, Perdu J, De Backer J, Bozec E, Collignon P, Emmerich J, Fauret AL, Fiessinger JN, Germain DP, Georgesco G, Hulot JS, De Paepe A, Plauchu H, Jeunemaitre X, Laurent S, Boutouyrie P: Effect of celiprolol on prevention of cardiovascular events in vascular Ehlers-Danlos syndrome: a prospective randomised, open, blinded-endpoints trial. Lancet. 2010 Oct 30;376(9751):1476-84. doi: 10.1016/S0140-6736(10)60960-9. Epub 2010 Sep 7. Pubmed
Products currently covered by valid US Patents are offered for R&D use in accordance with 35 USC 271(e)+A13(1). Any patent infringement and resulting liability is solely at buyer risk.

API’s From Quality Manufacturers:

  • Cost effective materials based on specific requirements
  • Small quantities for initial research and larger development quantities towards product commercialization


  • Technical packages, letters of access to filed DMFs
  • Complete assistance in any regulatory filings
  • Top quality GMP certified manufacturers
  • Have necessary regulatory credentials